Pro Medicus has signed a 10-year, A$128 million agreement with NYC Health + Hospitals to deploy its full Visage 7 enterprise imaging platform in the cloud. The transaction-based structure may provide additional upside, but the announcement does not disclose the expected revenue timing or volume profile.
- 10-year, A$128 million NYC Health + Hospitals contract
- Full Visage 7 Viewer, Workflow and Open Archive deployment
- Cloud implementation with legacy PACS migration
- Electronic health record integration across the health system
- Transaction-based model offers unquantified potential upside
A$128 million contract expands Pro Medicus' US footprint
Pro Medicus Limited (ASX:PME) has secured a 10-year, A$128 million contract with NYC Health + Hospitals, giving its Visage Imaging subsidiary one of its largest disclosed commercial agreements. The deal will deploy Pro Medicus' Visage 7 Enterprise Imaging Platform throughout the health system.
The agreement comes after the seven-year Virtua contract, another North American cloud imaging deal that included the Visage 7 platform, archive migration and electronic health record integration. Unlike a conventional fixed-fee arrangement, the new contract uses a transactional licensing model, meaning the disclosed A$128 million does not by itself establish a simple annual revenue run-rate.
Full Visage 7 stack moves into the cloud
NYC Health + Hospitals will receive the full stack: Visage 7 Viewer, Visage 7 Workflow and Visage 7 Open Archive. Pro Medicus will also migrate the organisation's legacy picture archiving and communication system, or PACS, archives into Open Archive.
The platform is intended to provide a unified diagnostic imaging environment, with enterprise-wide image distribution integrated into the health system's electronic health record. The announcement describes the implementation as cloud-based, but does not specify the cloud infrastructure, implementation cost or expected contribution from individual product modules.
Transaction volumes remain the key variable
The transaction-based structure creates potential for revenue above the contracted value, according to the announcement, although Pro Medicus has not quantified that upside. Nor has it provided an expected annual revenue profile, transaction-volume assumptions or details of the contract's termination terms.
That leaves the headline contract value useful as a measure of contracted opportunity, but insufficient on its own to determine how quickly the agreement will translate into reported revenue. The commercial model will make activity levels and the pace of clinical adoption important numbers once the rollout progresses.
Go-live targeted for late Q3 2027
Planning is due to begin immediately, with go-live targeted for late Q3 of calendar 2027. The timing gives Pro Medicus a defined implementation milestone, while leaving a substantial period between contract signing and production deployment.
The next evidence points are likely to be rollout progress, completion of the PACS migration and the scale of image transactions once the platform is live. For now, the contract strengthens Pro Medicus' disclosed order book while keeping the near-term revenue profile deliberately opaque.
Bottom Line?
The contract is substantial, but its investment significance will depend on implementation and transaction volumes rather than the headline value alone.
Questions in the middle?
- How will the A$128 million contract be recognised across the 10-year term?
- What transaction volumes could generate upside beyond the disclosed contract value?
- Will the late-Q3 2027 go-live target be met as legacy PACS archives are migrated?